ProMIS Neurosciences, Inc.
PMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.05 | -1.00 | -0.06 |
| FCF Yield | -110.62% | -76.71% | -52.32% | -19.58% |
| EV / EBITDA | 3.95 | -0.09 | -1.38 | -3.41 |
| Quality | ||||
| ROIC | -100.81% | -442.62% | -3,375.26% | -40.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -71,796.88% |
| Cash Conversion Ratio | -9.78 | 0.82 | 0.94 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 89.18% |
| Free Cash Flow Growth | -150.67% | 36.35% | -80.30% | -111.69% |
| Safety | ||||
| Net Debt / EBITDA | -4.65 | 0.71 | 0.45 | 1.77 |
| Interest Coverage | -219.18 | -93.84 | -82.89 | -19.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -274.08 | 0.00 | -32.26 |